Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 81, 2021 - Issue 4
Submit an article Journal homepage
432
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Performance comparison of commercial kits for isolating and detecting circulating tumor DNA

Mengyan WangDepartment of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, ChinaView further author information
,
Xia HuangDepartment of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, ChinaView further author information
,
Xin LiDepartment of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, ChinaView further author information
,
Qiaomei GuoDepartment of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, ChinaView further author information
,
Wanxing XuDepartment of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, ChinaView further author information
,
Mingna ZhaoDepartment of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, ChinaView further author information
,
Xueqing WangDepartment of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, ChinaView further author information
,
Lin WangDepartment of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, ChinaView further author information
&
Jiatao LouDepartment of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 276-281 | Received 05 May 2020, Accepted 15 Aug 2020, Published online: 17 May 2021

References

  • Przybyl J, Chabon JJ, Spans L, et al. Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma. Clin Cancer Res. 2018;24(11):2688–2699.
  • Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
  • Rothwell DG, Ayub M, Cook N, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019;25(5):738–743.
  • Khagi Y, Goodman AM, Daniels GA, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res. 2017;23(19):5729–5736.
  • Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990.
  • Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC – challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018;15(9):577–586.
  • Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–1209.
  • Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366–377.
  • Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012;18(8):2391–2401.
  • Sausen M, Leary RJ, Jones S, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2013;45(1):12–17.
  • Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer – a survey. Biochim Biophys Acta. 2007;1775(1):181–232.
  • Qin Z, Ljubimov VA, Zhou C, et al. Cell-free circulating tumor DNA in cancer. Chin J Cancer. 2016;35:36.
  • Underhill HR, Kitzman JO, Hellwig S, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12(7):e1006162.
  • Ladas I, Yu F, Leong KW, et al. Enhanced detection of microsatellite instability using pre-PCR elimination of wild-type DNA homo-polymers in tissue and liquid biopsies. Nucleic Acids Res. 2018;46(12):e74.
  • Xue X, Teare MD, Holen I, et al. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta. 2009;404(2):100–104.
  • Warton K, Graham L-J, Yuwono N, et al. Comparison of 4 commercial kits for the extraction of circulating DNA from plasma. Cancer Genet. 2018;228-229:143–150.
  • Pérez-Barrios C, Nieto-Alcolado I, Torrente M, et al. Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl Lung Cancer Res. 2016;5(6):665–672.
  • Diefenbach RJ, Lee JH, Kefford RF, et al. Evaluation of commercial kits for purification of circulating free DNA. Cancer Genet. 2018;228-229:21–27.
  • Solassol J, Quantin X, Larrieux M, et al. Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer. Clin Chem Lab Med. 2018;56(9):e243–e6.
  • Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–554.
  • Holmberg RC, Gindlesperger A, Stokes T, et al. Akonni TruTip(®) and Qiagen(®) methods for extraction of fetal circulating DNA – evaluation by real-time and digital PCR. PLoS One. 2013;8(8):e73068.
  • Sorber L, Zwaenepoel K, Deschoolmeester V, et al. A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. J Mol Diagn. 2017;19(1):162–168.
  • Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014;406(26):6499–6512.
  • Mauger F, Dulary C, Daviaud C, et al. Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma. Anal Bioanal Chem. 2015;407(22):6873–6878.
  • Perkins G, Yap TA, Pope L, et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One. 2012;7(11):e47020.
  • Guo K, Zhang Z, Han L, et al. Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer. Onco Targets Ther. 2015;8:3289–3296.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.